Skip to content
Awesome – Lifestyle
Author:
Alector, Inc.
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
April 30, 2026
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 5, 2026